What's Happening?
Dr. Sungwon Lim, CEO and Co-Founder of ImpriMed, has been invited to participate in a panel at the National Cancer Institute's (NCI) Precision in Practice: A Functional Medicine Workshop. The event, scheduled for July 1 and 2, 2026, at the NCI Shady Grove
Campus in Rockville, Maryland, will also be accessible online. Dr. Lim will contribute to discussions on 'Commercializing Functional Precision Medicine: Progress, Opportunities, and Challenges' alongside other industry leaders. The workshop aims to foster collaboration among academia, industry, government, and patient advocacy groups to advance the field of functional precision medicine over the next decade. ImpriMed is recognized for its innovative approach, using live cancer cells and artificial intelligence to predict treatment outcomes, which has been integrated into routine clinical use.
Why It's Important?
The inclusion of Dr. Lim in this panel underscores the growing importance of functional precision medicine in oncology. This approach, which uses live cancer cells to tailor treatments, represents a significant advancement over traditional genomic profiling. By predicting individual drug responses, it promises to enhance treatment efficacy and reduce costs. ImpriMed's participation highlights its leadership in this field, potentially influencing future cancer treatment protocols. The workshop's collaborative nature could accelerate the adoption of these technologies, benefiting patients by providing more personalized and effective treatment options.
What's Next?
The workshop is expected to outline future directions for functional precision medicine, potentially leading to broader clinical adoption. Stakeholders, including industry leaders and patient advocacy groups, will likely explore strategies to scale these technologies for wider use. The outcomes of these discussions could influence policy and funding decisions, impacting how quickly these innovations reach patients. ImpriMed's involvement positions it to play a key role in shaping these developments, potentially expanding its influence in both veterinary and human oncology.
